Brief: Fulcrum Therapeutics Announces Financial Results For The First Quarter 2023

Fulcrum Therapeutics

15/05/2023 12:18

May 15 (Reuters) - Fulcrum Therapeutics Inc  FULC.O :
    * FULCRUM THERAPEUTICS ANNOUNCES RECENT BUSINESS HIGHLIGHTS
AND
FINANCIAL RESULTS FOR THE FIRST QUARTER 2023
    * ON TRACK TO COMPLETE ENROLLMENT IN PHASE 3 REACH TRIAL OF
LOSMAPIMOD IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY DURING
2H'23
    * CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TO BE
SUFFICIENT
TO FUND OPERATING EXPENSES, CAPEX REQUIREMENTS INTO MID-2025
    * QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.41
    * Q1 EARNINGS PER SHARE VIEW $-0.46 -- REFINITIV IBES DATA
    * DISCUSSIONS CONTINUE WITH U.S. FDA TO RESOLVE CLINICAL
HOLD FOR
FTX-6058 IN SICKLE CELL DISEASE
    * AS OF MARCH 31, CASH, CASH EQUIVALENTS, MARKETABLE
SECURITIES
WERE $297.8 MILLION, VERSUS. $202.9 MILLION AS OF DEC 31, 2022

Source text for Eikon:  ID:nGNX3NbQN 
Further company coverage:  FULC.O